Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) EBT Margin (2016 - 2025)

Sangamo Therapeutics has reported EBT Margin over the past 16 years, most recently at 266.88% for Q4 2025.

  • Quarterly results put EBT Margin at 266.88% for Q4 2025, up 9963.0% from a year ago — trailing twelve months through Dec 2025 was 312.25% (down 13937.0% YoY), and the annual figure for FY2025 was 312.25%, down 14251.0%.
  • EBT Margin for Q4 2025 was 266.88% at Sangamo Therapeutics, up from 6039.76% in the prior quarter.
  • Over the last five years, EBT Margin for SGMO hit a ceiling of 21.78% in Q3 2024 and a floor of 10185.24% in Q1 2024.
  • Median EBT Margin over the past 5 years was 200.77% (2022), compared with a mean of 1819.13%.
  • Biggest five-year swings in EBT Margin: crashed -1019874bps in 2024 and later skyrocketed 1001850bps in 2025.
  • Sangamo Therapeutics' EBT Margin stood at 166.66% in 2021, then dropped by -14bps to 189.92% in 2022, then crashed by -1462bps to 2966.06% in 2023, then skyrocketed by 88bps to 366.51% in 2024, then rose by 27bps to 266.88% in 2025.
  • The last three reported values for EBT Margin were 266.88% (Q4 2025), 6039.76% (Q3 2025), and 109.03% (Q2 2025) per Business Quant data.